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Volume 71, Number 3a type II endoleak who later presented with a type I endoleak. A health status analysis between patients with an early
type II endoleak and patients with no endoleak was performed. Second, an attempt was made to identify risk factors in
patients with a type II endoleak who later presented with a type I endoleak.
Results: Through 5 years of follow-up, a total of 197 (15.6%) patients with isolated type II endoleaks were identified. Most
were detected within the first 30 days (n ¼ 73 [37.1%]) and through the first year (n ¼ 73 [37.1%]), with the remainder being
detected after 1 year of follow-up (n ¼ 51 [25.8%]). Patients with a type II endoleak had a higher incidence of aneurysm
growth andmore secondary endovascular procedures (15.4% vs 7.5% at 5 years; P < .001). Overall survival was higher in the
isolated type II endoleak group compared with patients with no endoleak (77.2% vs 67.0% at 5 years; P ¼ .010). Twenty-
two patients (10%) with a type II endoleak were diagnosed with a late type I endoleak (type IA, n ¼ 10; type IB, n ¼ 12), with
a secondary intervention rate of 67.5% through 5 years. There was no difference in health status scores between patients
with an early type II endoleak and patients without any type of endoleak at 1-year follow-up.
Conclusions: In the ENGAGE registry, isolated type II endoleaks are present in 15.6% of patients during follow-up. The
majority do not require secondary intervention, and an early isolated type II endoleak does not have an impact on health
status through 1 year. However, a small group of patients with a type II endoleakwill present with a type I endoleak, resulting
in a high secondary intervention rate and significant risk of aneurysm-related complications. (J Vasc Surg 2020;71:780-9.)
Keywords: EVAR; Endovascular; Abdominal aortic aneurysm; ENGAGE; Endoleak; Type IIThe occurrence of endoleaks after endovascular aneu-
rysm repair (EVAR) remains an issue. Type II endoleaks
are most common and arise from retrograde filling of
the aneurysm sac through collateral vessels, such as lum-
bar arteries or the inferior mesenteric artery.1,2 The inci-
dence of these endoleaks varies considerably by
imaging modality and contrast agent used but also
because some of them represent a low-flow aspect.
The early incidence is usually reported to be around
25%, but most resolve spontaneously during the first
6 months.3 Therefore, current treatment guidelines do
not recommend prompt treatment at the time of EVAR.
Previous studies on the natural course of type II endo-
leaks have shown that a conservative strategy is safe for
the majority of patients.4 However, up to 10% of type II
endoleaks persist, and a subset of themmay cause aneu-
rysm growth, in which case treatment should be consid-
ered.1,3,5 During follow-up, delayed isolated type II
endoleaks also occur; these are associated with an
increased number of secondary interventions.6 The exact
mechanism of these type II endoleaks is not well under-
stood. In case of a persistent type II endoleak, aneurysm
shrinkage is observed in 25%, a stable aneurysm sac in
50% to 70%, and sac enlargement in 15% to 25%. Rupture
due to apersistent type II endoleak is rarely reportedand is
estimated to occur in <1% of all type II endoleaks.1 To
further complicate matters, a systematic review showed
that about half of these ruptures occurred in the absence
of sac expansion.2 In case of aneurysm sac enlargement,
the presence of another type of endoleak (especially
type I or type III) should be suspected. A subset of patients
may have an unnoticed type I or type III endoleak as cause
of the type II endoleak, whereas somepatients with a type
II endoleakmay go on to develop a type I or type III endo-
leak. Although the exact underlying mechanism remains
unclear, a previous study showed that up to 21% of
patients who underwent a reintervention for a type II
endoleakhadanoccult type I or type III endoleak.7Currenttreatment guidelines vary from recommending treat-
ment of all type II endoleaks with sac enlargement to se-
lective intervention based on treatment options and the
patient’s existing comorbidities.3,5
Endovascular treatment options include transarterial
catheterization, perigraft arterial sac embolization, trans-
caval catheterization, and direct translumbar puncture
combined with coils or embolic agents to occlude the
feeding vessels. Open surgical options include either
laparoscopic ligation/clipping of the inferior mesenteric
artery or lumbar arteries and open surgical ligation of
feeding vessels or conversion to open repair.8,9 Reports
on the outcomes of reinterventions for persistent type II
endoleaks (with or without aneurysm growth) unani-
mously report high technical success rates. This may,
however, not be the best measure of success, as shown
by a recent review and meta-analysis of secondary inter-
ventions for type II endoleaks that again questions when
and if treatment is justified.10
This study aimed to report the incidence, natural his-
tory, and outcome of type II endoleaks in the largest pro-
spective real-world cohort to date, including a health
status analysis. Second, an analysis was performed to
identify potential risk factors in patients who were
initially diagnosed with a type II endoleak and later pre-
sented with a type I endoleak.
METHODS
Study design. Patients entered in the prospective
Endurant StentGraftNatural SelectionGlobal Postmarket
Registry (ENGAGE) were included. There were 79 partici-
pating centers worldwide, and ethical committee
approval was obtained for the majority of the sites
(>75%) andper local law. For the remaining centers, either
the ethical committee was notified or approval was
waived and standard of care treatment was followed for
the patients. The full registry design, inclusion and exclu-
sioncriteria, anddatacollectionandadetaileddescription
ARTICLE HIGHLIGHTS
d Type of Research: Prospectively collected registry
data (Endurant Stent Graft Natural Selection Global
Postmarket Registry [ENGAGE])
d Key Findings: In the ENGAGE registry, isolated type II
endoleaks occurred in 197 patients (15.6%) through
5 years after endovascular aneurysm repair. Although
most do not require secondary interventions,
patients with a type II endoleak had a higher inci-
dence of aneurysm growth and more secondary
endovascular procedures. Twenty-two patients
(10%) with a type II endoleak who were diagnosed
with a late type I endoleak had high secondary inter-
vention rates (67.5%) through 5 years. There was no
difference in health status scores between patients
with a type II endoleak and those without any type
of endoleak at 1-year follow-up.
d Take Home Message: A small group of patients with
a type II endoleak after endovascular aneurysm
repair will present with a type I endoleak, resulting
in a high secondary intervention rate and significant
risk of aneurysm-related complications.
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system have been previously published.11 In short, the
ENGAGE is a multicenter nonrandomized single-arm
prospective registry. Participating centers were required
to perform>20 EVAR procedures per annum. To increase
the real-world applicability of the ENGAGE outcomes,
both indication for intervention and follow-up protocols
were in accordance with standard clinical practice at the
participating sites.
The cohort of type II endoleaks was divided into two
groups. The first group consisted of patients who had
an isolated type II endoleak that was detected during
follow-up, excluding those that were present on periop-
erative angiography. The second group consisted of pa-
tients with a type II endoleak who were later diagnosed
with a type I endoleak. These groups were separate
and analyzed as such. Patients with a type II endoleak
and a type I endoleak at some point during follow-up
were not in the “isolated” type II group. The control group
consisted of patients who had no endoleak of any type
during follow-up. Baseline characteristics and outcomes
are reported and compared between these study groups.
Health status scores for patients with an early type II
endoleak vs patients without any type of endoleak
were obtained using the EuroQol-5 Dimension question-
naire and obtained at baseline, 30 days, and 1 year of
follow-up. To limit potential bias in this analysis, patients
with a concomitant endoleak of another type (type I or
type III) were excluded.
Definitions. Unless otherwise specified, outcomes are re-
ported in accordancewith current international treatment
guidelines and the Society for Vascular Surgery reporting
standards for endovascular aortic aneurysm repair.3,5,12
Isolated type II endoleak was defined as persistent
aneurysm sac filling through side branches, without
signs of either type I or type III endoleak, on duplex ultra-
sound, computed tomography angiography (CTA), mag-
netic resonance angiography, or angiography, without
signs of any other type of endoleak during subsequent
follow-ups.
Early isolated type II endoleak was defined as a type II
endoleak diagnosed #30 days of the index procedure.
Late isolated type II endoleak was defined as a type II
endoleak first diagnosed>30days of the index procedure.
Statistics. Descriptive statistics for categorical variables
were presented as relative frequencies (percentages).
Continuous variables were expressed as means, standard
deviations, medians, and ranges. For all other continuous
variables, the t-test was used. For group comparisons,
univariate analyses of categorical variables were per-
formed by using Cochran-Mantel-Haenszel test or
Fisher exact test; continuous variables were compared
using t-test or Wilcoxon rank sum test. Testing for
normality was not routinely performed; for variables thatare skewed by nature, the Wilcoxon rank sum test was
used. For the right-censored data, Kaplan-Meier survival
estimates were used to estimate the time-to-event and
survival rate. Namely, the freedom from conversion to
open surgery, secondary endovascular procedures,
aneurysm ruptures, and patient mortality (all-cause
mortality and aneurysm related mortality) were analyzed
using Kaplan-Meier method, and log-rank test was used
for subgroup comparisons. For the events observed from
the image data, instead of being observed at a specific
time point, time to event is reported within a time
interval. The survival function for such interval-censored
data was estimated using the EMICM algorithm (a
combination of expectation-maximization and iterative
convex minorant algorithms). The time-to-event com-
parisons were conducted using log-rank test. Two sided
P values #.05 were considered statistically significant. All
statistical analyses were performed with SAS 9.4 software
(SAS Institute, Carey, NC).
RESULTS
The ENGAGE registry included 1263 patients (89.5%
men; mean age, 73.1 years [range, 43-93 years]). At
completion angiography (t ¼ 0), 181 (14.3%) type II endo-
leaks were identified, of which 105 (58.0%) had spontane-
ously resolved at the first follow-up imaging. Follow-up
data on endoleaks were available for 1090 (86.4%)
patients. During follow up (t ¼ 1 and onward), a total of
197 (15.6%) patients with isolated type II endoleaks were
identified and 893 (70.8%) patients without any endo-
leak. Baseline characteristics are shown in Table I. The
Table I. Baseline characteristics, isolated type II endoleak vs no endoleak
Isolated type II endoleak (n ¼ 197) No endoleak (n ¼ 893) P value
Age, years 73.8 6 8.1 72.7 6 8.1 .078
Male sex 88.8 (175/197) 89.9 (803/893) .694
Smoking 35.4 (68/192) 53.4 (465/871) <.001
Hypertension 81.0 (158/195) 73.8 (649/879) .036
Hyperlipidemia 68.9 (131/190) 59.4 (498/838) .015
Diabetes 18.4 (36/196) 19.6 (172/878) .695
Cardiac disease 56.3 (111/197) 53.1 (474/892) .414
Pulmonary disease 24.2 (47/194) 25.9 (227/877) .632
Renal insufficiency 15.9 (31/195) 14.9 (132/885) .729
Aneurysm characteristics
Maximum diameter, mm 59.3 6 9.7 59.7 6 11.3 .633
Proximal neck diameter, mm 23.1 6 3.4 23.7 6 3.5 .032
Proximal neck length, mm 27.5 6 11.6 27.0 6 12.6 .585
Proximal neck angle, degrees 31.2 6 23.0 29.2 6 23.2 .284
Proximal neck length <15 mm 6.1 (12/197) 12.7 (112/883) .009
Continuous data are presented as mean 6 standard deviation and categorical data as % (n/N).
Table II. Baseline characteristics, early vs late type II endoleak
Early (#30 days) type II endoleak
(n ¼ 73)
Late (>30 days) type II endoleak
(n ¼ 124) P value
Age, years 74.6 6 8.3 73.3 6 7.9 .269
Male sex 87.7 (64/73) 89.5 (111/124) .692
Smoking 26.8 (19/71) 40.5 (49/121) .055
Hypertension 78.9 (56/71) 82.3 (102/124/) .563
Hyperlipidemia 73.5 (50/68) 66.4 (81/122) .309
Diabetes 15.3 (11/72) 20.2 (25/124) .396
Cardiac disease 57.5 (42/73) 55.6 (69/124) .797
Pulmonary disease 20.8 (15/72) 26.2 (32/122) .398
Renal insufficiency 11.1 (8/72) 18.7 (23/123) .163
Aneurysm characteristics
Maximum diameter, mm 59.6 6 11.1 59.2 6 8.3 .798
Proximal neck diameter, mm 22.9 6 2.9 23.3 6 3.7 .411
Proximal neck length, mm 29.4 6 11.6 26.4 6 4.1 .076
Proximal neck angle, degrees 31.4 6 25.6 31.0 6 21.5 .918
Proximal neck length <15 mm 1.4 (1/73) 8.9 (11/124) .034
Continuous data are presented as mean 6 standard deviation and categorical data as % (n/N).
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Volume 71, Number 3majority of patients were detected within the first
30 days (early type II endoleaks, n ¼ 73 [37.1%]; Table II)
and through the first year (n ¼ 73 [37.1%]) after surgery
(Fig 1). Several imaging modalities were used, including
CTA (n ¼ 138 [70.1%)], duplex ultrasound (n ¼ 54
[27.4%]), angiography (n ¼ 4 [2.0%]), and magnetic reso-
nance angiography (n ¼ 1 [0.5%]).
Isolated type II endoleak vs no endoleak. Indication for
EVAR did not differ between the isolated type II and the
no endoleak groups. Hypertension and hyperlipidemiaincidences were significantly higher in the isolated type
II endoleak group, whereas the incidence of smoking
was higher in the no endoleak group. Aneurysm charac-
teristics were mostly similar, with a slightly smaller prox-
imal neck diameter (23.1 mm vs 23.7 mm; P ¼ .032) in the
isolated type II endoleak group. There was a higher inci-
dence of short neck aneurysms in the no endoleak group
(12.7% vs 6.1% in the isolated type II group; P ¼ .009;
Table I).
During follow-up, there was a significant difference in
aneurysm diameter change between the two groups.
Fig 1. Kaplan-Meier analysis, freedom from isolated type II endoleak.
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March 2020Patients with an isolated type II endoleak had a higher
incidence of aneurysm growth, and this steadily
increased during follow-up and reached significance
after 3 years of follow-up (P < .001; Table III). Freedom
from secondary endovascular procedures was 94.3%,
91.0%, 89.1%, 84.6%, and 79.2% in the isolated type II
group compared with 94.9%, 94.5%, 94.1%, 93.6%, and
92.5% in the no endoleak group through 1, 2, 3, 4, and
5 years, respectively (P < .0001; Fig 2). A secondary endo-
vascular procedure that aimed to correct an isolated
type II endoleak was performed in 34 patients (17.3%).
Two aneurysm ruptures were reported. One occurred in
a patient with an isolated type II endoleak who had sta-
ble aneurysm size during follow-up, and one occurred in
a patient who initially had no endoleak but developed a
type IA endoleak with growth seen on follow-up imaging
3 years after the initial procedure. Freedom from
aneurysm-related mortality through 5 years was 99.5%
in the isolated type II group compared with 99.0% in
the no endoleak group (P ¼ .57). Overall survival was
95.4%, 90.2%, 85.9%, 80.4%, and 77.2% (through 1, 2, 3,
4, and 5 years, respectively) in the isolated type II group
compared with 93.5%, 86.9%, 79.5%, 73.1%, and 67.0%
in the no endoleak group (P ¼ .010; Fig 3). There were
no differences in health status scores between patients
with an early type II endoleak vs patients without any
endoleak at any time point (Table III).
Early vs late isolated type II endoleak. A subanalysis of
isolated type II endoleaks that were first identified within
30 days after EVAR vs those that were first identified after
30 days showed a higher incidence of shorter neck aneu-
rysms in the delayed type II group (n ¼ 11 [8.9%])compared with the early type II group (n ¼ 1 [1.4%];
P ¼ .034); however, the difference in mean neck length
did not reach statistical significance (29.4 mm vs
26.4 mm; P ¼ .076; Table II). There was no significant
difference in the remaining baseline characteristics or
aneurysm morphology.
Isolated type II vs type II and late type I endoleak.
Twenty-two patients with a type II endoleak were diag-
nosed with a late type I endoleak (type IA, n ¼ 10; type
IB, n ¼ 12) during follow-up. These were analyzed
separately from the group that had an isolated type II
endoleak. The late type I endoleaks were diagnosed at a
median of 1205 days after the initial procedure (822-
1716 days) using CTA (n ¼ 18 [81.8%]) and duplex
ultrasound (n ¼ 4 [18.2%]). The median time between
diagnosis of the type II endoleak and the type I endoleak
was 969 days (631-1451 days).
The sole significant difference found in the baseline
characteristics was a proximal neck length of <15 mm.
In the group that developed a late type I endoleak,
25.0% (5/20) had a short neck aneurysm vs 6.1% (12/197)
in the isolated type II group, although there was no
significant difference in absolute infrarenal neck length
(27.5 6 11.6 mm compared with 24.4 6 10.0 mm;
P ¼ .242). There was no difference in iliac sealing zone
length, infrarenal neck angle, or maximal aneurysm
diameter. Aneurysm rupture occurred in 4 of 22 (18.2%)
patients with type II endoleak who later developed
type I endoleaks. This was fatal in one patient (4.5%)
with type II endoleaks. Freedom from aneurysm rupture
was 99.5% at 5 years for the isolated type II group vs
80.2% for the late type I group (P < .0001). Freedom
Table III. Follow-up data, isolated type II endoleak vs no endoleak
Isolated type II endoleak (n ¼ 197) No endoleak (n ¼ 893) P value
AAA diameter change 1 year
Decrease 31.5 (52/165) 45.4 (306/674) .001
Stable 63.6 (105/165) 52.2 (352/674) .009
Increase 4.8 (8/165) 2.4 (16/674) .113
AAA diameter change 2 years
Decrease 42.1 (59/140) 60.4 (337/558) <.001
Stable 50.7 (71/140) 37.1 (207/558) .004
Increase 7.1 (59/140) 2.5 (14/588) .016
AAA diameter change 3 years
Decrease 43.1 (53/123) 68.6 (310/452) <.001
Stable 42.3 (52/123) 28.8 (130/452) .006
Increase 14.6 (18/123) 2.7 (12/452) <.001
AAA diameter change 4 years
Decrease 41.3 (45/109) 71.1 (288/405) <.001
Stable 40.4 (44/109) 25.4 (103/405) .003
Increase 18.3 (20/109) 3.5 (14/405) <.001
AAA diameter change 5 years
Decrease 40.6 (39/96) 72.1 (246/341) <.001
Stable 37.5 (36/96) 24.6 (84/341) .014
Increase 21.9 (21/96) 3.2 (11/341) <.001
EuroQol-5 Dimension index
Baseline 0.88 6 0.15 0.86 6 0.17 .161
12 months 0.90 6 0.15 0.88 6 0.16 0428
Early (#30 days) type II endoleak (n ¼ 73) No endoleak (n ¼ 893) P value
EuroQol-5 Dimension index
Baseline 0.86 6 0.17 0.86 6 0.17 .867
12 months 0.88 6 0.18 0.88 6 0.16 .938
AAA, Abdominal aortic aneurysm.
Continuous data are presented as mean 6 standard deviation and categorical data as % (n/N).
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type I group (99.5% vs 90%; P ¼ .003).
In this subgroup with a late type I endoleak, the
secondary endovascular procedure rate was signifi-
cantly higher, reaching 67.5% through 5 years vs
21.8% in the isolated type II group (P < .0001;
Fig 4). In the group with no endoleak, the 5-year
reintervention rate was 7.5% (Fig 2). A total of 14
secondary endovascular procedures in 12 patients
that aimed to correct the type I endoleak were per-
formed. Of the secondary endovascular procedures,
nine (75%) were successful in treating the type I
endoleak.
DISCUSSION
The overall incidence of isolated type II endoleaks in the
ENGAGE registry is in line with earlier publications.1,2 The
data confirm that the majority of isolated type II endo-
leaks are clinically not of concern. However, they also
show that having a type II endoleak is associated withan increased risk of aneurysm growth and a higher inci-
dence of secondary interventions. Moreover, a small
group of patients with a type II endoleak presented
with a late type I endoleak during follow-up, which resul-
teds in a 67.5% secondary endovascular procedure rate
through 5 years, increased aneurysm rupture risk, and
aneurysm-related mortality. The exact pathophysiologic
mechanism is unclear. In the introduction, two possible
hypothesizes have been described. First, a type II endo-
leak may lead to aneurysmal disease progression and
subsequent type I (A or B) endoleak. Second, a type II
endoleak may be a type I (A or B) endoleak in disguise.
Besides the exact pathophysiologic mechanism, the rela-
tively high incidence of late type I endoleak suggests that
in these cases, a conservative strategy might be cata-
strophic. This is supported by the larger subset of
patients with aneurysm growth. Larger aneurysms tend
to have a shorter neck length. A higher incidence of
neck dilation in relation to type II endoleak, however,
has not been described in the literature, and based on
Fig 2. Kaplan-Meier analysis, freedom from secondary endovascular procedures comparing patients with isolated
type II endoleak vs no endoleak.
Fig 3. Kaplan-Meier analysis, freedom from all-cause mortality comparing patients with isolated type II endoleak
vs no endoleak.
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missed. A recent publication showed that endograft
apposition and expansion of the aortic neck may predict
late type IA endoleak, but no correlation with type II
endoleak was found in that small series.13 Also, the ability
to detect endoleaks varies between imaging modalities
and imaging protocols. Nonetheless, the fact that a sub-
set of patients with a type II endoleak later presented
with a type I endoleak, some well after the index proced-
ure, confirms the need for meticulous follow-up in thesepatients. It could also be advocated that patients with a
new type II endoleak with duplex ultrasound should un-
dergo further evaluation to make sure this not related
to another type of endoleak. Although, given the registry
design, no definitive conclusions can be made, patients
with short-neck aneurysms and type II endoleaks may
be at a higher risk for development of a late type I endo-
leak, which corresponds with earlier publications on this
matter.14-16 In this study, smoking was associated with a
lower incidence of type II endoleaks. Given the
Fig 4. Kaplan-Meier analysis, freedom from secondary endovascular procedures comparing patients with late
type I endoleak vs isolated type II endoleak.
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observed difference is not necessarily causal, although
there have been previous studies that showed smoking
was associated with lower incidence of type II endo-
leaks.17 However, even if smoking were to be protective,
it would be unwise to have patients smoke to prevent
type II endoleaks.
Interestingly, freedom from all-cause mortality was
higher in patients with an isolated type II endoleak vs
patients without an endoleak of any type (77.2% vs 67.0%
through 5 years of follow-up, respectively; P ¼ .010; Fig 3).
This corresponds with an earlier publication4 in which the
authors found survival to be higher in the type II endoleak
group compared with patients with no endoleak, espe-
cially in the subgroup of late-occurring type II endoleaks.
In this study, no protocol for reintervention was used and
was left at the discretion of the treating physician. Only
nine reinterventionswereperformed,mostly for sac expan-
sion >10 mm. No good explanation for this phenomenon
was found. A possible reason could be that follow-up in
patients with a type II endoleak is moremeticulous, which
could in turn result in a lower aneurysm-related mortality
(also causing lower all-cause mortality). However, loss to
follow-up did not differ between groups, and a significant
difference between follow-up schemes was not found in
the current cohort. Cancer was a common cause of death
for patients in both the no endoleak group (24.2%, 65/268
deaths were due to some form of cancer) as well as for
those patients with isolated type II endoleaks (28.6%, 12/
42 deaths were due to some form of cancer). The overall
aneurysm-related mortality is low, and there is nosignificant difference in aneurysm-relatedmortality for pa-
tients with an isolated type II endoleak compared with
those without any type of endoleak. This is in contrast to
thosewhowere later diagnosedwith a late type I endoleak.
Unfortunately, these two groups cannot be distinguished
beforehand.
The presented data corroborate previous publications
showing that the risk of aneurysm rupture for type II
endoleaks is low. Patients with an isolated type II endo-
leak did show a higher incidence of aneurysm growth
during longer term follow-up, but rupture may have
occurred only once in the isolated type II endoleak group.
This should be interpreted with caution, however; a reli-
able cause of death is notoriously difficult to obtain, and
the incidence of rupture may be higher. Secondary endo-
vascular procedures were more common in the type II
group andmight be in part responsible for this result. Sec-
ondary endovascular procedures were performed for type
II endoleaks in 21.8% of patients vs a secondary endovas-
cular procedure rate of 7.5% in the group without endo-
leaks. The main indication for secondary intervention
was aneurysm sac expansion. In patients that developed
a type I endoleak, secondary endovascular procedures
were even more frequent. For a type I endoleak, which
is considered a high-pressure and therefore high-risk
endoleak, there is no arguing that this needs to be
resolved if there is a suitable treatment option for the pa-
tient. For an isolated type II endoleak, this is far less clear.
In this series, 34 patients with isolated type II endoleaks
underwent a secondary endovascular procedure. Howev-
er, only a subset of patients with an isolated type II
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ical sequelae or even rupture. It is unknown which pa-
tients will benefit from secondary endovascular
procedures. The current European guidelines advocate a
more “relaxed” surveillance protocol in “low-risk” patients
(no endoleak, good seal) but yearly follow-up in case of
an isolated type II endoleak.18 Based on the presented
data, a less strict follow-up scheme might be safe,
although further studies are needed to confirm these
findings and to justify a change in surveillance strategy.
In a broader perspective, risk factors for the develop-
ment of an isolated type II endoleak have been identi-
fied, but the exact pathophysiologic mechanism
remains unknown. This is especially frustrating in late
type II endoleaks. These late type II endoleaks do occur,
but seemingly without cause. The literature on these
endoleaks is scarce, but recent publications have sug-
gested that these “late” type II endoleaks might be less
benign compared with “early,” leading to more sac
expansion and high reintervention rates. This could war-
rant more vigilant follow-up protocols.19 It is important to
note in the referred study, late type II endoleaks were
defined as those occurring >1 year after EVAR compared
with >30 days in this study.
There was no difference in health status scores
between the no endoleak group and the early isolated
type II endoleak group both at 30 days and at 1 year
(Table III). Apparently, having a type II endoleak and the
potentially intensified follow-up do not have an impact
on health status, at least in the short term.
This study has limitations. First, the inherent limitations
of registries apply, and not all patients had follow-up
data on the occurrence of type II endoleaks available.
The follow-up protocols were not dictated by the
ENGAGE registry and varied between participating cen-
ters, which could have influenced outcomes. Data avail-
able for analysis are limited to the data as reported on
the case report forms. The ENGAGE case report form
has broad categories for additional devices used during
the implantation procedure. Because the “other” category
could include anything from aortouni-iliac devices to
cuffs, coils, and limb extensions, a direct comparison of
specific additional devices was not possible. In this study,
patients who showed signs of an isolated type II endoleak
on completion angiography that had disappeared on the
first postoperative follow-up imaging were considered
benign and excluded from further analysis. On the other
hand, the possibility of this subgroup of patients also hav-
ing a higher risk of aneurysm growth or the development
of a late type I endoleak remains unknown as we do not
have these data. Specifically for the health status analysis,
follow-up was modest and limited to 1 year. The ENGAGE
registry does not use a core laboratory for image analysis.
The sensitivity of duplex ultrasound scans in detecting
type II endoleaks may differ between sites, which could
affect our results. However, previous publications haveshown that both duplex ultrasound and contrast-
enhanced duplex ultrasound have good sensitivity and
specificity in detecting type II endoleaks compared with
CTA.20 The decision to perform a secondary endovascular
procedure aimed to correct an isolated type II endoleak
was at the treating physician’s discretion. Ultimately, the
registry data are descriptive and not designed to prove
or disprove a hypothesis; it is a tool to gain more insight
and to guide further research.
CONCLUSIONS
In the ENGAGE registry, isolated type II endoleaks are
present in 15.6% of patients during follow-up. The major-
ity are clinically not of concern. Having an early isolated
type II endoleak does not have an impact on health sta-
tus through 1 year. A small group of patients with a type II
endoleak will present with a type I endoleak that is asso-
ciated with a high secondary intervention rate and risk of
aneurysm-related complications.
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